Important Notice for Cardlytics, Inc. (CDLX) Shareholders
New York, NY, February 10, 2025 – The Gross Law Firm, a leading securities fraud class action law firm, issues this notice to all investors who purchased or otherwise acquired Cardlytics, Inc. (CDLX) common stock between October 1, 2023 and December 31, 2024, inclusive (the “Class Period”).
What’s Going On?
The Gross Law Firm is investigating potential securities fraud claims on behalf of shareholders concerning possible violations of federal securities laws. Specifically, the investigation concerns whether Cardlytics and certain of its officers and/or directors made false and/or misleading statements and/or failed to disclose material information during the Class Period.
Why Should I Care?
If you purchased or otherwise acquired CDLX common stock during the Class Period, you may be entitled to recover your losses, including damages. The lead plaintiff position is subject to approval by the court, and the lead plaintiff will be a representative party acting on behalf of all shareholders in the proposed class. If you wish to serve as the lead plaintiff, you must meet certain legal requirements and must file a motion with the court before the deadline set by the court.
What’s Next?
If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact The Gross Law Firm as soon as possible at 888-440-09-10. You may also reach the firm by email at [email protected]. If you are a member of this class, you can view a detailed description of the securities class action lawsuit against Cardlytics, Inc. and certain of its officers and/or directors, including the complaint, on the firm’s website at
How Does This Affect Me?
If you purchased CDLX common stock during the Class Period, you may have lost money as a result of the alleged securities fraud. The investigation is ongoing, but if the allegations are proven true, shareholders may be able to recover their losses through a securities class action lawsuit.
How Does This Affect the World?
The potential securities fraud allegations against Cardlytics could have implications for the financial industry as a whole. If the allegations are proven true, it could lead to increased scrutiny of other companies in the industry, potentially resulting in further investigations and lawsuits. Additionally, it could negatively impact investor confidence in the financial industry, making it more difficult for companies to raise capital and grow.
Conclusion
If you purchased CDLX common stock during the Class Period, it’s important to stay informed about the investigation and any potential developments. The Gross Law Firm is dedicated to helping investors recover their losses and will keep shareholders updated on the progress of the investigation. If you have any questions or would like to discuss your rights and interests, please don’t hesitate to contact the firm.
- The Gross Law Firm is investigating potential securities fraud claims against Cardlytics, Inc. and certain of its officers and/or directors.
- Shareholders who purchased CDLX common stock during the Class Period may be entitled to recover their losses, including damages.
- The investigation is ongoing, but if the allegations are proven true, shareholders may be able to recover their losses through a securities class action lawsuit.
- The potential securities fraud allegations against Cardlytics could have implications for the financial industry as a whole.
- Investors who purchased CDLX common stock during the Class Period are encouraged to contact The Gross Law Firm for more information.
